中東およびアフリカの甲状腺がん診断市場 – 2030 年までの業界動向と予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

中東およびアフリカの甲状腺がん診断市場 – 2030 年までの業界動向と予測

  • Medical Devices
  • Published Report
  • Feb 2023
  • MEA
  • 350 ページ
  • テーブル数: 146
  • 図の数: 47

中東およびアフリカの甲状腺がん診断市場

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2024 –2030
Diagram 市場規模(基準年)
USD MILLION
Diagram Market Size (Forecast Year)
USD 416.82
Diagram CAGR
%
Diagram 主要市場プレーヤー
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

中東およびアフリカの甲状腺がん診断市場、製品タイプ別(機器、消耗品、付属品)、検査タイプ別(画像検査、生検、血液検査、その他)、がんの種類別(乳頭がん、濾胞がん、その他)、ステージ別(ステージ I、ステージ II、ステージ III、ステージ IV)、年齢層別(21 歳未満、21~29 歳、30~65 歳、65 歳以上)、エンドユーザー別(病院、関連研究所、独立診断研究所、診断画像センター、がん研究機関、その他)、流通チャネル別(直接入札、小売販売) - 2030 年までの業界動向と予測。

中東およびアフリカの甲状腺がん診断市場

中東およびアフリカの甲状腺がん診断市場の分析と洞察

甲状腺がんに対する意識の高まりにより、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に貢献しています。主要な市場プレーヤーは、この重要な時期にさまざまなサービスの立ち上げと承認に重点を置いています。さらに、診断プロセスと技術の改善の増加も、甲状腺がんの診断検査の需要の増加に貢献しています。

中東およびアフリカの甲状腺がん診断市場

中東およびアフリカの甲状腺がん診断市場

中東およびアフリカの甲状腺がん診断市場は、2023年から2030年の予測期間に成長すると予想されています。データブリッジマーケットリサーチは、市場は2023年から2030年の予測期間に4.8%のCAGRで成長し、2030年までに4億1,682万米ドルに達すると分析しています。

レポートメトリック

詳細

予測期間

2023年から2030年

基準年

2022

歴史的な年

2021 (2020~2015年にカスタマイズ可能)

定量単位

収益(百万米ドル)

対象セグメント

製品タイプ別(機器、消耗品、付属品)、検査タイプ別(画像検査、生検、血液検査、その他)、がんの種類別(乳頭がん、濾胞がん、その他)、ステージ別(ステージ I、ステージ II、ステージ III、ステージ IV)、年齢層別(21 歳未満、21~29 歳、30~65 歳、65 歳以上)、エンドユーザー別(病院、関連ラボ、独立診断ラボ、診断画像センター、がん研究機関、その他)、流通チャネル別(直接入札、小売販売)

対象国

南アフリカ、サウジアラビア、UAE、エジプト、イスラエル、その他の中東およびアフリカ

対象となる市場プレーヤー

キヤノン株式会社、富士フイルムホールディングス株式会社、F. ホフマン・ラ・ロシュ株式会社、クエスト・ダイアグノスティクス株式会社、イルミナ、フィリップス社、サーモフィッシャーサイエンティフィック株式会社、シーメンスヘルスケア株式会社、アボット、ゼネラルエレクトリックカンパニー、BD、キアゲン、ディアソリンSPA、メルクKGaA、ホロジック、ミリアドジェネティクス株式会社、ビオメリュー、FONAR株式会社、タイムメディカルホールディングス、プレックスバイオ、ミンファウンドメディカルシステムズ株式会社、メドニカ株式会社、北京O&Dバイオテック株式会社、シュテルンメッド株式会社など

市場の定義

Thyroid cancer is a type of cancer that starts in the thyroid gland. Cancer starts when cells begin to grow out of control. The thyroid gland makes hormones that help regulate your metabolism, heart rate, blood pressure, and body temperature. The thyroid gland is in the front part of the neck, below the thyroid cartilage (Adam's apple). In most people, the thyroid cannot be seen or felt. It is shaped such as a butterfly, with two lobes — the right lobe and the left lobe — joined by a narrow piece of the gland called the isthmus.

Middle East and Africa Thyroid Cancer Diagnostics Market Dynamics

DRIVERS

RISING INCIDENCE AND PREVALENCE OF THYROID NODULES & CANCER

A thyroid nodule is an unusual growth (lump) of thyroid cells in the thyroid gland. Sometimes the normal thyroid soft tissue started to grow, causing these nodules to form. Nodule incidence increases with age and mainly in women, mainly in those with iodine deficiency and after radiation exposure. Although the further complication of these nodules is thyroid cancer, the chances of converting thyroid nodules to thyroid cancer are low. According to an article published in NCBI named "Risk of Malignancy in Thyroid Nodules 4 cm or Larger" in 2017, cancer occurrence after nodules is found in less than 5% of the total nodules cases. Moreover, the thyroid nodules run in the family history and in people whose iodine intake is low.

RISING THYROID CANCER DIAGNOSTIC TESTS

Thyroid ultrasound is a sound wave picture of the thyroid gland taken by a hand-held instrument and translated to a 2-dimensional picture on a monitor. It is used in the diagnosis of tumors, cysts, or goiters of the thyroid and is a painless, no-risk procedure. These tests are used to evaluate structural anomalies, whereas blood tests measuring TSH, T4, and T3 levels are used to examine functional variables. Fine needle biopsy is used in suspicious cases to determine whether a tumor is benign or malignant. Furthermore, the introduction of molecular testing and the genetic prognosis fuel the diagnostic landscape in this market for thyroid cancer diagnostics.

RISING AWARENESS TOWARDS THYROID CANCER

Growing thyroid cancer awareness has led to an increased demand for timely cancer detection, leading to market growth.

Thyroid cancer is one of the major causes of rising mortality rates among U.S. populations worldwide, fueling the market growth over the next five years. Exposure to radiation and a family history of thyroid issues are major risk factors for thyroid cancer. Women are diagnosed with thyroid cancer significantly more than men.

RESTRAINS

HIGH COST OF DIAGNOSTICS PROCEDURE

Cancer diagnostics have become increasingly expensive due to the growing number of thyroid cancer patients and the rising medical device prices. The modern technological devices used in cancer diagnostic is also playing a significant role in the high prices of cancer diagnostics, and high accuracy, in providing a definitive diagnosis for cancer in thyroid nodules. Therefore, the high cost of diagnostics procedures for thyroid cancers is hampering the growth of the market.

The diagnostic products or devices which are used in the detection of cancer are becoming advanced but along with that, the procedure for cancers diagnostics are also costly, which hamper the growth of the thyroid cancer diagnostics market because the devices are used in the process of cancer diagnosis getting more expensive which results to increase in the cost of diagnostics procedure. Thus, the high cost of diagnostics for cancer diagnosis acts as a restraint for the Middle East and Africa thyroid cancer diagnostics market.

TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS

High radiation exposure causes significant tissue damage and raise a person's chance of later acquiring cancer. Although it's vital to keep this risk in context, the tiny radiation doses used for imaging tests may marginally raise a person's risk of developing cancer. The amount of radiation a person receives varies on the test's kind, the area of their body that is exposed, their body size, age, and gender, among other things. Imaging examinations that employ radiation should only be performed when necessary because radiation exposure from all sources can mount up over a lifetime and can increase the chance of developing cancer. Other imaging procedures like ultrasound or MRI may also be utilized often.

OPPORTUNITIES

RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT

Across the globe, R&D activities are escalating owing to public health expenditure with economic performances whereas, the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of R&D opportunities. It is anticipated to upsurge the demand for ovarian cancer diagnostics.

Increasing healthcare expenditure for cancer treatment also helps patients to take hassle-free advanced diagnostics and treatment for fast recovery. Healthcare spending is made up of out-of-pocket payments (people paying for their own care), government expenditure, and sources, including health insurance and activities by Non-Governmental Organizations (NGOs). Due to this increasing healthcare expenditure for cancer treatment, it acts as an opportunity for market growth.

CHALLENGES

STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS

The stringent regulations for the approval and commercialization of any product in the market are proving to be one of the major challenges for manufacturers of cancer diagnostic products in the U.S. and European region. Every country has regulations and a different body for regulatory procedures.

The potential regulatory pathways are mandatory for clearance, approval, or acceptance of complex signatures by the U.S. Food and Drug Administration (FDA). The regulatory pathways include regulations applicable to In Vitro Diagnostic (IVD) devices, including companion diagnostic devices, the potential for labeling as a complementary diagnostic, and the biomarker qualification program.

Recent Developments

  • In August 2022, F. Hoffmann-La Roche Ltd, announced the launch of the Digital LightCycler System, Roche's first digital polymerase chain reaction (PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods. This has helped the company to increase its Middle East and Africa presence in the market
  • In May 2022, Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Thermo Scientific Glacios 2 Cryo-Transmission Electron Microscope (Cryo-TEM), a powerful microscope with new automation and high-resolution imaging capabilities designed to help cryo-electron microscopy (cryo-EM) researchers of varying experience levels accelerate structure-based drug discovery. This advanced, fast, and cost-efficient method for drug design may enable customers to accelerate the pace of research for debilitating disorders like Alzheimer's, Parkinson's, and Huntington's diseases, as well as research for cancer and gene mutations

Middle East and Africa Thyroid Cancer Diagnostics Market Scope

The Middle East and Africa thyroid cancer diagnostics market is segmented into product type, test type, cancer type, stages, age group, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

  • Instruments
  • Consumables & Accessories

On the basis of product type, the Middle East and Africa thyroid cancer diagnostics market is segmented into instruments and consumables & accessories.

Test Type

  • Imaging Test
  • Blood Test
  • Biopsy
  • Others

On the basis of test type, the Middle East and Africa thyroid cancer diagnostics market is segmented into imaging test, blood test, biopsy and others.

Cancer Type

  • Papillary Carcinoma
  • Follicular Carcinoma
  • Others

On the basis of cancer type, the Middle East and Africa thyroid cancer diagnostics market is segmented into papillary carcinoma, follicular carcinoma, and others.

Stages

  • Stage I
  • Stage II
  • Stage III
  • Stage IV

On the basis of stages, the Middle East and Africa thyroid cancer diagnostics market is segmented into stage I, stage II, stage III and stage IV.

Age Group

  • 30-65
  • 65 and above
  • 21-29
  • Below 21

On the basis of age group, the Middle East and Africa thyroid cancer diagnostics market is segmented into 30-65, 65 and above, 21-29, and below 21.

End User

  • Hospitals
  • Associated Labs
  • Independent Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
  • Others

On the basis of end user, the Middle East and Africa thyroid cancer diagnostics market is segmented into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales

On the basis of distribution channel, the Middle East and Africa thyroid cancer diagnostics market is segmented into direct tender and retail sales.

甲状腺がん診断市場

Middle East and Africa Thyroid Cancer Diagnostics Market Regional Analysis/Insights        

The Middle East and Africa thyroid cancer diagnostics market is analysed, and market size insights and trends are provided by country, product type, test type, cancer type, stages, age group, end user, and distribution channel, as referenced above.

The countries covered in this market report are South Africa, Saudi Arabia, U.A.E, Egypt, Israel, and Rest of Middle East and Africa.

Saudi Arabia is expected to dominate the Middle East and Africa thyroid cancer diagnostics market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the rising incidence and prevalence of thyroid nodules & cancer.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and African brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Thyroid Cancer Diagnostics Market Share Analysis

中東およびアフリカの甲状腺がん診断市場の競争環境は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、中東およびアフリカでのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、中東およびアフリカの甲状腺がん診断市場に関連する会社の焦点にのみ関連しています。

中東およびアフリカの甲状腺がん診断市場で活動している主要企業には、キヤノン株式会社、富士フイルムホールディングス株式会社、F. ホフマン・ラ・ロシュ株式会社、クエスト・ダイアグノスティクス社、イルミナ、フィリップス社、サーモフィッシャーサイエンティフィック社、シーメンスヘルスケア社、アボット社、ゼネラル・エレクトリック社、BD、キアゲン社、ディアソリン社、メルク社、ホロジック社、ミリアド・ジェネティクス社、バイオメリュー社、FONAR社、タイム・メディカル・ホールディングス社、プレックスバイオ社、ミンファウンド・メディカル・システムズ社、メドニカ社、北京O&Dバイオテック社、スターンメッド社などがあります。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET TESTING TYPE COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS

5 EPIDEMIOLOGY

6 REGULATORY FRAMEWORK OF THE MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET

6.1 REGULATORY SCENARIO IN THE U.S.

6.2 REGULATORY SCENARIO IN AUSTRALIA

6.3 REGULATORY SCENARIO IN JAPAN

6.4 REGULATORY SCENARIO IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER

7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS

7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS

7.1.4 RISING AWARENESS TOWARDS THYROID CANCER

7.2 RESTRAINTS

7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE

7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS

7.3 OPPORTUNITIES

7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT

7.3.2 RISING OBESE POPULATION

7.4 CHALLENGES

7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS

7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE

8 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 INSTRUMENTS

8.2.1 PATHOLOGY BASED INSTRUMENTS

8.2.1.1 PCR INSTRUMENTS

8.2.1.2 SLIDE STAINING SYSTEMS

8.2.1.3 TISSUE PROCESSING SYSTEMS

8.2.1.4 CELL PROCESSORS

8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS

8.2.2 IMAGING INSTRUMENTS

8.2.2.1 ULTRASOUND SYSTEMS

8.2.2.2 CT SYSTEMS

8.2.2.3 MRI SYSTEMS

8.2.2.4 OTHERS

8.2.3 BIOPSY INSTRUMENTS

8.2.3.1 NEEDLE BIOPSY

8.2.3.2 ENDOSCOPIC BIOPSY

8.2.3.3 CORE BIOPSY

8.2.3.4 OTHERS

8.2.4 OTHERS

8.3 CONSUMABLES & ACCESSORIES

8.3.1 KITS

8.3.1.1 PCR KITS

8.3.1.2 DNA POLYMERASE KITS

8.3.1.3 NUCLEIC ACID ISOLATION KITS

8.3.1.4 OTHERS

8.3.2 REAGENTS

8.3.2.1 ASSAYS

8.3.2.2 BUFFERS

8.3.2.3 PRIMERS

8.3.2.4 OTHERS

8.3.3 PROBES

8.3.4 OTHER CONSUMABLES

9 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE

9.1 OVERVIEW

9.2 IMAGING TEST

9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN

9.2.2 MRI

9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN

9.2.4 OTHERS

9.3 BLOOD TEST

9.3.1 BLOOD CHEMISTRY TESTS

9.3.2 COMPLETE BLOOD COUNT (CBC)

9.3.3 OTHERS

9.4 BIOPSY

9.4.1 NEEDLE BIOPSY

9.4.2 BRONCHOSCOPY BIOPSY

9.4.3 CORE BIOPSY

9.4.4 OTHERS

9.5 OTHERS

10 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 PAPILLARY CARCINOMA

10.3 FOLLICULAR CARCINOMA

10.4 OTHERS

11 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES

11.1 OVERVIEW

11.2 STAGE I

11.3 STAGE II

11.4 STAGE III

11.5 STAGE IV

12 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP

12.1 OVERVIEW

12.2 30-65

12.3 65 AND ABOVE

12.4 21-29

12.5 BELOW 21

13 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 ASSOCIATED LABS

13.4 INDEPENDENT DIAGNOSTIC LABORATORIES

13.5 DIAGNOSTIC IMAGING CENTERS

13.6 CANCER RESEARCH INSTITUTES

13.7 OTHERS

14 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

15 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY REGION

15.1 MIDDLE EAST AND AFRICA

15.1.1 SAUDI ARABIA

15.1.2 U.A.E.

15.1.3 SOUTH AFRICA

15.1.4 EGYPT

15.1.5 ISRAEL

15.1.6 REST OF MIDDLE EAST AND AFRICA

16 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 CANON INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 COMPANY SHARE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENTS

18.2 FUJIFILM CORPORATION

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.3 F. HOFFMANN-LA ROCHE LTD

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 QUEST DIAGNOSTICS INCORPORATED

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENTS

18.5 ILLUMINA, INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 ABBOTT

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 BD

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 BEIJING O&D BIOTECH CO., LTD.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENTS

18.9 BIOMÉRIEUX SA

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENTS

18.1 DIASORIN S.P.A.

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 PRODUCT PORTFOLIO

18.10.4 RECENT DEVELOPMENT

18.11 FONAR CORP.

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 GENERAL ELECTRIC

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 HOLOGIC INC.

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENT

18.14 KONINKLIJKE PHILIPS N.V.

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 PRODUCT PORTFOLIO

18.14.4 RECENT DEVELOPMENT

18.15 MERCK KGAA.

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 MEDONICA CO. LTD

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 MINFOUND MEDICAL SYSTEMS CO. LTD

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENTS

18.18 MYRIAD GENETICS, INC.

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENTS

18.19 PLEXBIO.

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENTS

18.2 QIAGEN

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

18.21 STERNMED GMBH

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENTS

18.22 SIEMENS HEALTHCARE GMBH

18.22.1 COMPANY SNAPSHOT

18.22.2 REVENUE ANALYSIS

18.22.3 PRODUCT PORTFOLIO

18.22.4 RECENT DEVELOPMENT

18.23 TIME MEDICAL HOLDING.

18.23.1 COMPANY SNAPSHOT

18.23.2 PRODUCT PORTFOLIO

18.23.3 RECENT DEVELOPMENT

18.24 THERMO FISHER SCIENTIFIC INC.

18.24.1 COMPANY SNAPSHOT

18.24.2 REVENUE ANALYSIS

18.24.3 PRODUCT PORTFOLIO

18.24.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

表のリスト

TABLE 1 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA PAPILLARY CARCINOMA IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA FOLLICULAR CARCINOMA IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA STAGE I IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA STAGE II IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA STAGE III IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA STAGE IV IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA 30-65 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA 65 AND ABOVE IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA 21-29 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA BELOW 21 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA HOSPITALS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA ASSOCIATED LABS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA DIAGNOSTIC IMAGING CENTERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA DIRECT TENDER IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA RETAIL SALES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 59 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 61 SAUDI ARABIA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 62 SAUDI ARABIA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 63 SAUDI ARABIA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 64 SAUDI ARABIA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 65 SAUDI ARABIA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 66 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 67 SAUDI ARABIA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 68 SAUDI ARABIA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 69 SAUDI ARABIA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 70 SAUDI ARABIA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 71 SAUDI ARABIA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 72 SAUDI ARABIA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 73 SAUDI ARABIA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 74 SAUDI ARABIA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 75 SAUDI ARABIA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 76 SAUDI ARABIA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 77 SAUDI ARABIA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 78 U.A.E. THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 79 U.A.E. INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 80 U.A.E. PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 81 U.A.E. IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 82 U.A.E. BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 83 U.A.E. CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 84 U.A.E. KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 85 U.A.E. REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 86 U.A.E. THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 87 U.A.E. IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 88 U.A.E. BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 89 U.A.E. BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 90 U.A.E. THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 91 U.A.E. THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 92 U.A.E. THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 93 U.A.E. THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 94 U.A.E. THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 95 SOUTH AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 96 SOUTH AFRICA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 SOUTH AFRICA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 98 SOUTH AFRICA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 99 SOUTH AFRICA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 100 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 101 SOUTH AFRICA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 102 SOUTH AFRICA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 103 SOUTH AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 104 SOUTH AFRICA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 105 SOUTH AFRICA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 106 SOUTH AFRICA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 107 SOUTH AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 108 SOUTH AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 109 SOUTH AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 110 SOUTH AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 111 SOUTH AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 112 EGYPT THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 113 EGYPT INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 114 EGYPT PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 115 EGYPT IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 116 EGYPT BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 117 EGYPT CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 118 EGYPT KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 119 EGYPT REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 120 EGYPT THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 121 EGYPT IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 122 EGYPT BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 123 EGYPT BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 124 EGYPT THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 125 EGYPT THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 126 EGYPT THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 127 EGYPT THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 128 EGYPT THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 129 ISRAEL THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 130 ISRAEL INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 131 ISRAEL PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 132 ISRAEL IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 133 ISRAEL BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 134 ISRAEL CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 135 ISRAEL KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 136 ISRAEL REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 137 ISRAEL THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 ISRAEL IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 139 ISRAEL BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 140 ISRAEL BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 141 ISRAEL THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 142 ISRAEL THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 143 ISRAEL THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 144 ISRAEL THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 145 ISRAEL THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 146 REST OF MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

図表一覧

FIGURE 1 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT THYROID CANCER IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD

FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET

FIGURE 14 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022

FIGURE 15 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 17 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022

FIGURE 19 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 21 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022

FIGURE 23 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 25 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, 2022

FIGURE 27 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030)

FIGURE 29 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE

FIGURE 30 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022

FIGURE 31 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 32 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 33 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 34 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 35 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 36 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 37 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 39 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 40 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 41 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 43 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 44 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 45 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 46 MIDDLE EAST AND AFRICA THYROID CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)

FIGURE 47 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Middle East and Africa thyroid cancer diagnostics market size will be worth USD 416.82 million by 2030.
The growth rate of the Middle East and Africa thyroid cancer diagnostics market is 4.8%.
Rising incidence and prevalence of thyroid nodules & cancer & rising thyroid cancer diagnostic tests are the growth drivers of the Middle East and Africa thyroid cancer diagnostics market.
Product type, test type, cancer type, stages, age group, end user, and distribution channel are the factors on which the Middle East and Africa thyroid cancer diagnostics market research is based.
Major companies in the Middle East and Africa thyroid cancer diagnostics market are Canon Inc., FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Illumina, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Abbott, General Electric Company, BD, QIAGEN, DIASORIN S.P.A., Merck KGaA, Hologic, Myriad Genetics Inc., BIOMERIEUX, FONAR Corp., Time Medical Holding., PlexBio., MinFound Medical Systems Co., Ltd, Medonica Co. LTD, Beijing O&D Biotech Co., Ltd., and SternMed GmbH. among others.